| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Beverly Moy | Q117222983 |
| P2093 | author name string | Paul E Goss | |
| P2860 | cites work | VEGF-targeted therapy in metastatic renal cell carcinoma | Q34406737 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | management recommendation | Q124146017 |
| P304 | page(s) | 756-765 | |
| P577 | publication date | 2007-07-01 | |
| P1433 | published in | Oncologist | Q2122327 |
| P1476 | title | Lapatinib-associated toxicity and practical management recommendations | |
| P478 | volume | 12 |
| Q37947902 | Beyond trastuzumab: new treatment options for HER2-positive breast cancer |
| Q43514509 | Brain metastases from HER2-positive breast cancer |
| Q35490056 | Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations |
| Q37791732 | Cardiac toxicity in breast cancer patients: From a fractional point of view to a global assessment |
| Q38005052 | Cardiac toxicity of targeted therapies used in the treatment for solid tumours: a review |
| Q34095748 | Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast Cancer |
| Q35955198 | Combination drug delivery approaches in metastatic breast cancer |
| Q60193666 | Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) pseudokinase in cancer cells. |
| Q41561441 | Drug delivery approaches for breast cancer |
| Q39307190 | EGFR inhibitors erlotinib and lapatinib ameliorate epidermal blistering in pemphigus vulgaris in a non-linear, V-shaped relationship |
| Q54389879 | Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours. |
| Q37338228 | Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer |
| Q34598522 | ErbB2 receptor over-expression improves post-traumatic peripheral nerve regeneration in adult mice |
| Q38095989 | Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. |
| Q35622862 | HER2: biology, detection, and clinical implications |
| Q37823570 | Heart failure caused by molecularly targeted therapies for cancer |
| Q37782086 | Lapatinib and breast cancer: current indications and outlook for the future |
| Q37281586 | Lapatinib and ixabepilone for the treatment of metastatic breast cancer |
| Q35042071 | Lapatinib combined with neoadjuvant paclitaxel-trastuzumab-based chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: A meta-analysis of randomized controlled trials |
| Q37810946 | Lapatinib for breast cancer: a review of the current literature |
| Q34372166 | Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence |
| Q39836265 | Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial |
| Q40355268 | Lapatinib-induced acute generalized exanthematous pustulosis |
| Q37605777 | Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer |
| Q37355729 | Lapatinib: new opportunities for management of breast cancer |
| Q92051297 | Liposomal Lapatinib in Combination with Low-Dose Photodynamic Therapy for the Treatment of Glioma |
| Q34241118 | Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib |
| Q57069976 | Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities |
| Q35663802 | Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ. |
| Q37196543 | Molecular target therapies in endometrial cancer: from the basic research to the clinic. |
| Q37491455 | Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients |
| Q37275470 | Pharmacogenetics in drug discovery and development: a translational perspective |
| Q37554942 | Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2. |
| Q36963374 | Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer |
| Q34095753 | Practical Management Recommendations for Anti-ErbB2 Therapy with Lapatinib |
| Q37785387 | Prevention and management of major side effects of targeted agents in breast cancer |
| Q33920661 | Promising novel therapies for the treatment of endometrial cancer |
| Q37355762 | Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer |
| Q34096239 | Safety Profile and Clinical Recommendations for the Use of Lapatinib |
| Q34363419 | Targeted treatment of advanced and metastaticbreast cancer with lapatinib. |
Search more.